Getty Images In time for what I've been calling "Follow-up Friday" lately, I focus on REITs again and revisit American Healthcare REIT ( AHR ), which recently had earnings results on Feb. 26th and is up around +83% since my original coverage in 2024 , when I recommended holding on to it. In subsequent articles, I continued saying hold, including this past December, and some continuing positive ele...
Getty Images In time for what I've been calling "Follow-up Friday" lately, I focus on REITs again and revisit American Healthcare REIT ( AHR ), which recently had earnings results on Feb. 26th and is up around +83% since my original coverage in 2024 , when I recommended holding on to it. In subsequent articles, I continued saying hold, including this past December, and some continuing positive elements I liked were portfolio growth and macro forecasts favoring senior care and outpatient facilities. A concern I had was lower EBITDA margins than some peers, as well as a weaker dividend growth case. For readers new to this stock, AHR operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man, according to its profile, and in today's follow-up, I'll be rating it across 8 rating categories that include both fundamental and technical aspects of this stock. Thesis Summary Based on my updated research, I am upgrading this stock to a buy from my prior hold ratings, and the worksheet below shows how my 8 rating categories contributed to the overall score: AHR - rating worksheet (author) Despite having a limited dividend growth history due to only having gone public in 2024, AHR definitely wins in several factors, including continuing macro-level demand for senior care and outpatient services, a robust portfolio growth and development pipeline, improved NOI and FFO growth, a low D/E and real estate portfolio generating positive operating cash flow, positive price forecasts, and technical patterns supporting a bullish view. Macro & Sector Outlook In considering what macroeconomic factors can impact this sector AHR is in, I first considered the specific niche this REIT is in within the overall healthcare space, and that is a combination of senior care, skilled nursing, and outpatient facilities in the US and UK, as shown in its portfolio page : AHR - portfolio segments (company website) Knowing that, what comes to mind right aw...
Legendary investor and Berkshire Hathaway's Vice Chairman, Charlie Munger's investment into BYD Co. Ltd. in 2008 made the company a sizeable profit. However, Berkshire’s timely exit came right before the automaker reported a decline in sales. Charlie Munger's BYD Investment Trung Phan, a user on the social media platform X on Monday, quoted a post that outlined a decline in BYD sales over the firs...
Legendary investor and Berkshire Hathaway's Vice Chairman, Charlie Munger's investment into BYD Co. Ltd. in 2008 made the company a sizeable profit. However, Berkshire’s timely exit came right before the automaker reported a decline in sales. Charlie Munger's BYD Investment Trung Phan, a user on the social media platform X on Monday, quoted a post that outlined a decline in BYD sales over the first two months of 2026. He shared how Munger's investment in the EV giant turned into a profitable venture. Quoting Munger, he shared that the investor, in an interview, outlined that he had "never helped do anything at Berkshire that was as good as BYD." Munger had gotten the company to invest $230 million into the Chinese EV giant back in 2008 for a 10% stake in the company. Don't Miss: However, the company began exiting its position in BYD in the year 2022 and ultimately sold the entirety of its stake in the automaker by the third quarter of 2025, "basically right before sales drop," Phan said. Charlie Munger said "I have never helped do anything at Berkshire that was as good as BYD" by getting it to invest $230m for 10% of the company in 2008. Berkshire started selling it in 2022 and completely exited by Q3 2025, basically right before sales drop. Made $9B, which was… https://t.co/9xPcW7cjpq BYD's Sales Draw Concern From Elon Musk Tesla Inc. CEO Elon Musk also reacted to the drop in sales reported by BYD, sharing that factories running at 50% below capacity meant "mega pain" for the automaker. Trending: Disney Was Built on Character IP — This Pre-IPO Company Is Using the Same Playbook BYD reported a 36% drop in its domestic sales during February as it was overtaken in sales by fellow Chinese automaker Geely Automobile Holdings Ltd. for the first two months of the year. BYD's Overseas Sales Despite the domestic decline, BYD's overseas sales remain a strong point for the brand as it reported sustained growth in Europe. During January, BYD sold over 18,242 units in the regio...